Ivan Griffin
Fondatore presso BENEVOLENTAI
Posizioni attive di Ivan Griffin
Società | Posizione | Inizio | Fine |
---|---|---|---|
BENEVOLENTAI | Direttore operativo | 01/02/2014 | - |
Fondatore | 01/11/2013 | - | |
BenevolentAI Cambridge Ltd.
BenevolentAI Cambridge Ltd. Miscellaneous Commercial ServicesCommercial Services BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom. | Direttore/Membro del Consiglio | 29/05/2019 | - |
Storia della carriera di Ivan Griffin
Precedenti posizioni note di Ivan Griffin
Società | Posizione | Inizio | Fine |
---|---|---|---|
Nesta Investment Management LLP
Nesta Investment Management LLP Investment ManagersFinance Nesta Investment Management LLP. (NESTA Investments) subsidiary of Nesta formerly NESTA, is a venture capital firm founded in 1998. The firm is headquartered in London city United Kingdom. | Investitore di Private Equity | 19/11/2009 | 01/01/2014 |
Cerogenix Ltd.
Cerogenix Ltd. Miscellaneous Commercial ServicesCommercial Services Cerogenix Ltd. provides pharmaceutical research and development services. The company focuses on developing therapeutics for the treatment of neurological diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. Cerogenix was founded in September, 2005 by Adrian Pini and is located in London, UK | Direttore/Membro del Consiglio | 12/09/2005 | 24/08/2007 |
Segretario Aziendale | 12/09/2005 | 24/08/2007 | |
BenevolentAI Ltd.
BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Direttore operativo | 17/09/2015 | - |
Fondatore | 17/09/2015 | - | |
Corporate Officer/Principal | 17/09/2015 | - | |
Sirigen Group Ltd.
Sirigen Group Ltd. Chemicals: Major DiversifiedProcess Industries Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality. | Direttore/Membro del Consiglio | 08/12/2010 | - |
IP GROUP PLC | Corporate Officer/Principal | - | - |
Formazione di Ivan Griffin
University of Oxford | Doctorate Degree |
Statistiche
Distribuzione geografica
Regno Unito | 8 |
Lussemburgo | 2 |
Posizioni
Director/Board Member | 3 |
Corporate Officer/Principal | 2 |
Chief Operating Officer | 2 |
Settori
Commercial Services | 4 |
Consumer Services | 2 |
Process Industries | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
IP GROUP PLC | Commercial Services |
BENEVOLENTAI | Health Technology |
Aziende private | 5 |
---|---|
BenevolentAI Cambridge Ltd.
BenevolentAI Cambridge Ltd. Miscellaneous Commercial ServicesCommercial Services BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom. | Commercial Services |
Cerogenix Ltd.
Cerogenix Ltd. Miscellaneous Commercial ServicesCommercial Services Cerogenix Ltd. provides pharmaceutical research and development services. The company focuses on developing therapeutics for the treatment of neurological diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. Cerogenix was founded in September, 2005 by Adrian Pini and is located in London, UK | Commercial Services |
Sirigen Group Ltd.
Sirigen Group Ltd. Chemicals: Major DiversifiedProcess Industries Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality. | Process Industries |
Nesta Investment Management LLP
Nesta Investment Management LLP Investment ManagersFinance Nesta Investment Management LLP. (NESTA Investments) subsidiary of Nesta formerly NESTA, is a venture capital firm founded in 1998. The firm is headquartered in London city United Kingdom. | Finance |
BenevolentAI Ltd.
BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Technology Services |
- Borsa valori
- Insiders
- Ivan Griffin
- Esperienza